Personalis, Inc.

We’re honored to have recently celebrated our 5-year listing anniversary on NASDAQ! We’ve continuously been a leader in advanced genomics for cancer, and have strived to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. #PrecisionOncology #Genomics #NGS

"Using #genome information, Bay Area-based Personalis, Inc. created a blood test that detected evidence of breast #cancer tumors up to 15 months earlier than traditional imaging." Following findings shared at #ASCO24, Personalis's Chief Medical Officer Dr. Richard Chen appeared on NBC Bay Area this week to highlight the success the company's Personal NeXT platform has seen in detecting early recurrence of #breastcancer

Join us on Tuesday, June 18, from 1:00 pm - 2:00 pm EDT for a webinar highlighting new data in breast cancer and immunotherapy monitoring presented at ASCO 2024. In a breast cancer study with The Royal Marsden, NeXT Personal® found that 100% of patients with undetectable residual disease in repeat testing did not have cancer recurrence. ctDNA detection correctly identified disease recurrence with a 15-month median lead time over imaging detection in all 14 patients that relapsed. Learn more about this study and other data from ASCO, including: - Immunotherapy treatment monitoring, pan-cancer with prognostic and predictive results - Therapy monitoring in patients with gastrointestinal (GI) cancers Some of our key partners and collaborators include The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Dana-Farber Cancer Institute, Duke Cancer Institute , and Vall d'Hebron Institute of Oncology (VHIO). Register today: https://bit.ly/4aUaRD7 #PrecisionOncology #Liquidbiopsy #BreastCancer #GastrointestinalCancer #ctDNA #ASCO24

"We really focus on the mission and what we’re trying to do — we’re trying to make an impact in people’s lives. Many people took jobs at Personalis because they’re giving this to cancer patients. That really motivates them." Read Personalis, Inc. CEO Christopher Hall's executive profile interview with Ron Leuty in the San Francisco Business Times to learn more about the company's groundbreaking efforts in minimal residual disease testing and more.

Exciting news about cancer detection breakthroughs coming from #Personalis ! https://lnkd.in/ghGkRuFJ #ASCO

Compelling data presented at #ASCO24 by our collaborators at the Dana-Farber Cancer Institute from the DAPHNe trial. In a study of patients with early stage HER2+ breast cancer receiving neoadjuvant paclitaxel/trastuzumab/ pertuzumab (THP), 50 were sequenced with NeXT Personal®, which demonstrated 92% baseline detection (27% of detections were in the ultra-sensitive range below 100 PPM). NeXT Personal was also able to demonstrate neoadjuvant THP treatment effectiveness by showing the treatment had cleared the tumor MRD. #PrecisionOncology #ctDNA #ImmunoTherapy

Take a look at this poster from #ASCO24 presented by Dr. Andrew Nixon from Duke Cancer Institute and Dr. Fábio C. P. Navarro from Personalis highlighting data in patients with late-stage esophagogastric cancer that received immunotherapy in combination with chemotherapy as part of the KeyLargo trial. Dr. Nixon found that ctDNA levels were demonstrated to be highly prognostic for therapy response. In late-stage cancer patients, ctDNA levels can be very low with ~20% of samples falling in the ultra-sensitive range, underscoring the importance of an ultra-sensitive test like NeXT Personal®. #ImmunoTherapy #PrecisionOncology #LiquidBiopsy #ctDNA

Take a look at this poster from #ASCO24 presented by Dr. Andrew Nixon from Duke Cancer Institute and Dr. Fábio C. P. Navarro from Personalis highlighting data in patients with late-stage esophagogastric cancer that received immunotherapy in combination with chemotherapy as part of the KeyLargo trial. Dr. Nixon found that ctDNA levels were demonstrated to be highly prognostic for therapy response. In late-stage cancer patients, ctDNA levels can be very low with ~20% of samples falling in the ultra-sensitive range, underscoring the importance of an ultra-sensitive test like NeXT Personal®. #ImmunoTherapy #PrecisionOncology #LiquidBiopsy #ctDNA

Compelling data presented at #ASCO24 by our collaborators at the Dana-Farber Cancer Institute from the DAPHNe trial. In a study of patients with early stage HER2+ breast cancer receiving neoadjuvant paclitaxel/trastuzumab/ pertuzumab (THP), 50 were sequenced with NeXT Personal®, which demonstrated 92% baseline detection (27% of detections were in the ultra-sensitive range below 100 PPM). NeXT Personal was also able to demonstrate neoadjuvant THP treatment effectiveness by showing the treatment had cleared the tumor MRD. #PrecisionOncology #ctDNA #ImmunoTherapy

“NeXT Personal demonstrated the best MRD [assay] performance we have seen in [the Royal Marsden Breast Cancer] study cohort,” said Dr. Isaac Garcia-Murillas, lead author and Staff Scientist at the Institute of Cancer Research, London. “With the ultra-sensitive performance of NeXT Personal, we see strong opportunities to impact breast cancer care and management, especially for the escalation and de-escalation of treatment.” Key data highlights from Dr. Garcia’s podium talk at ASCO 2024: - NeXT Personal’s Ultra-sensitive range enabled earlier detection of recurrence, with a median ~15-month lead time over imaging detection - 100% of patients that recurred were detected with NeXT Personal and 100% of patients that were ctDNA negative on longitudinal testing were cancer-free - NeXT Personal enabled detection of very low traces of cancer, with ~39% of all detections falling in the ultra-sensitive range below 100 PPM (below 0.01% of ctDNA) - NeXT Personal enabled substantially better sensitivity and lead times compared to other MRD assays on the same patient cohort For the full Personalis ASCO 2024 data summary, see our recent press release: https://bit.ly/3RePIN0 #PrecisionOncology #MRD #ctDNA #LiquidBiopsy